A Korean Filler Made From Donors' Skin Is Drawing Chinese Beauty Tourists, and Doctors Warn the Evidence Is Thin

A skin filler made from tissue donated by dead people has become one of the most sought-after procedures in South Korea's medical-aesthetics scene, and Chinese beauty tourists are flying in for it — even as doctors on both sides of the border warn that the evidence behind the product is thinner than its marketing.

The product, Elravie Re2O from the Korean biotech firm L&C BIO, is an injectable made from the skin of deceased donors. Donated skin is stripped of cells and genetic material, leaving a "purified scaffold" of collagen and elastin known as extracellular matrix, which is milled into particles and injected into the face; the idea is that the scaffold gives the patient's own cells something to grow on, prompting them to produce fresh collagen. On Chinese social media it has picked up an unpromising nickname — the "corpse-skin needle" — alongside glowing first-person reports. One commenter in a thread on the trend said that even after a month of late nights her skin stayed luminous, and that she was already planning a return trip.

The trips are not cheap. Hongxing News, the outlet that took the story national this week, put the going rate around 3,000 yuan an injection; one Guangdong woman who flew to Korea in August told China News Weekly she paid 750,000 won — about 3,750 yuan — for a single shot after a Korean dermatologist recommended it, without having researched the product beforehand. Re2O is approved and sold in South Korea, Japan and Singapore, but not China, which makes every Chinese patient in a Seoul clinic a medical tourist accepting a product her own regulator has never reviewed.

The core of the case against it is that the science has not caught up with the demand. The early study behind Re2O's claims of smoother, brighter skin ran for only 20 weeks, was small, and — as industry watchers have been pointing out since the reports appeared — its participants were the product's own developers. The British aesthetician Ben Taylor-Davies, quoted in the Chinese coverage, called the marketing far ahead of the verification. Xue Ke, who leads plastic surgery at a hospital in Shanghai's Pudong district, said that because injections of donated human tissue — "allograft" material — lack clinical data, patients should expect five to ten years of follow-up before the product's real effects are known. Chen Youbai, a member of a Chinese plastic-and-reconstructive surgery committee, flagged two sharper risks: current decellularization cannot remove every cell component, so donor gene fragments may survive in the injection, and because the matrix is a composite of many substances, a problem would be far harder to trace than with a single-ingredient filler. Even a leading Seoul dermatologist, No Seongmin, told Korean media that quality differences tied to the donor's age may persist at the molecular level despite processing.

Chinese comment sections have split into the two camps that now greet every cross-border beauty fad: those who argue that results are the only test that matters, and those who say the risks are being sanded out of the sales pitch. Underneath the argument sits a genuine regulatory gap — a product can be licensed in Seoul, injected into a tourist from Guangzhou, and exist in a zone where no authority on either side has signed off on its long-term safety. For now, the product's real verdict sits queued behind the follow-up its critics say it needs — five to ten years of watching the people who have already had it.